“The use of these drugs, called thrombolytic therapy, can limit damage and disability due to blood clots,” said study author Kennedy R. Lees, MD, of the University of Glasgow in Scotland. “However, current guidelines can keep people from receiving the therapy if they have a history of stroke and diabetes.”
For the study, scientists gathered data from 23,062 people who received clot-busting therapy along with 6,166 people who did not receive clot-busting therapy. Measurements of how well people were able to function 90 days after the stroke were taken from both groups. A total of 19 percent of the people had diabetes and 17 percent had a prior stroke.
Stroke outcomes were measured on a scale of zero to six using the modified Rankin Scale. Zero represented no symptoms, three represented moderate disability meaning a person requires some help but is able to walk unassisted and a six indicated death.
The study found that 43 percent of people with diabetes who received the clot-busting therapy had a disability score of two or less, compared with only 34 percent of diabetes patients who did not receive the therapy. Additionally, the study found 48 percent of patients with previous stroke who received clot-busting therapy scored a two or less, compared with 35 percent of patients with previous stroke who did not receive the therapy.
“Better outcomes with therapy show that people with prior stroke or diabetes should not be excluded from receiving thrombolytic therapy,” said Lees.
The study was supported by the Virtual International Stroke Trials Archive (VISTA), the University of Glasgow and the European Stroke Organization. VISTA is a not for profit collaboration of clinical scientists that aims to make clinical trial data available for further research.
The American Academy of Neurology, an association of more than 24,000 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as Alzheimer’s disease, stroke, migraine, multiple sclerosis, brain injury, Parkinson’s disease and epilepsy.
For more information about the American Academy of Neurology, visit http://www.aan.com.VIDEO: http://www.youtube.com/AANChannel
Rachel L. Seroka | American Academy of Neurology
The Great Unknown: Risk-Taking Behavior in Adolescents
19.01.2017 | Max-Planck-Institut für Bildungsforschung
A sudden drop in outdoor temperature increases the risk of respiratory infections
11.01.2017 | University of Gothenburg
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences